Table 2.
Studies assessing the effect of colonoscopy surveillance interval in LS
| Study | Ref. | Subjects | Inclusion criteria | Setting | CS Interval | Findings |
|---|---|---|---|---|---|---|
| Järvinen, 2000 | [3] | 252 | Amsterdam criteria and LS, gene tested | Prospective, controlled non-randomized trial | 3 years | CRC reduced 62% in 15 years compared to not screened.Mortality reduced 65% vs. no CS surveillance. Adherence 93%. |
| Dove-Edwin, 2005 | [13] | 290 | Amsterdam criteria | Retrospective | 3 years | Estimated 72% reduction of CRC mortality when screened. Adherence not reported. |
| Mecklin, 2007 | [4] | 420 | LS, gene tested | Prospective, observational | 3 years | Estimated risk for CRC 22% for women and 35% for men before age 60. No increase in CRC mortality compared to non-carriers. Adherence 98%. |
| Järvinen, 2009 | [14] | 242 | LS, gene tested | Prospective, controlled non-randomized observational | 3 years | CRC incidence 12.4% in 11·5 years, no increase in CRC mortality compared to non-carriers. Adherence 96%. |
| De vos tot Nederveen Cappel, 2002 | [15] | 857 | Amsterdam criteria or gene tested | Retrospective | 2-3 years | 10.5% cumulative CRC risk in 10 years under surveillance. Lower tumor stage if CS interval < 2 years. |
| Stormorken, 2007 | [5] | 601 | Amsterdam criteria or gene tested | Prospective, observational | 2-3 years | CRC incidence of LS carriers not increased compared to non-carriers. Adherence not reported. |
| Newton, 2015 | [6] | 227 | LS, gene tested | Retrospective | 2-3 years | CRC incidence 25% at age 70. Adherence 87%. |
| Stupart, 2009 | [16] | 178 | LS, MLH1 mutation | Prospective, controlled non-randomized observational | 1-2 years | CRC incidence 11% in 5 years compared to 27% if no surveillance. Adherence not reported. |
| Vasen, 2010 | [7] | 745 | LS, gene tested | Retrospective | 1-2 years | CRC cumulative risk 6% in 7·2 years. Adherence not reported. |
| Engel, 2010 | [17] | 622 | LS, gene tested | Prospective, controlled non-randomized observational | 1-2 years | CRC cumulative risk at age 60 23%, early stages. Adherence 81% to 15 months. |
| Stuckless, 2012 | [18] | 152 | LS, MSH2 mutation | Retrospective | 1-2 years | CRC reduced 71% in 10 years, interval cancers 27% in males and 15% in females. Adherence 44%. |
LS Lynch syndrome
CRC colorectal cancer
CS colonoscopy